Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Royal Marsden NHS Foundation Trust
OBJECTIVES:
* To test the feasibility of delivering hypofractionated intensity-modulated radiotherapy to the prostate and pelvic nodes of patients with prostate cancer.
* To determine the optimal dose level of this treatment regimen to be used in future studies.
OUTLINE: Patients are stratified according to small bowel total volume (low small bowel volume \< 450 cc vs high small bowel volume ≥ 450 cc).
Patients undergo hypofractionated intensity-modulated radiotherapy to the prostate and pelvis for 4 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 5 years and then annually thereafter.
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Diagnosis of prostate cancer meeting 1 of the following criteria:
* Stage T3b/T4 disease or radiological or pathological pelvic nodal metastases
* Localized disease (stage pT2-T4) with \> 30% estimated risk of pelvic nodal metastases
* High-risk (Gleason score ≥ 8 or ≥ 2 risk factors) or very high-risk disease according to the National Collaborative Cancer Network (NCCN)
* Has undergone prostatectomy AND has stage T2-T3a, N0 disease with extensive high-risk disease (Gleason score ≥ 8) or seminal vesicle or lymph node involvement
Candidate for radical radiotherapy
PATIENT CHARACTERISTICS:
No inflammatory bowel disease or other small bowel disease
PRIOR CONCURRENT THERAPY:
No prior pelvic radiotherapy or surgery (excluding prostatectomy)
Clareo Health | Intensity-Modulated Radiation Therapy in Treating Patients With Prostate Cancer
